CURX: Curanex Pharmaceuticals Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Financial Statements and Exhibits
Stocks in this Quantisnow insightHealth Care
Historical context for CURX
Across the 3 sessions after earlier CURX headlines, the stock closed higher 2 times and lower 1 times, with a median move of 5.0% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | CURX | SPY |
|---|---|---|---|
| Mar 5, 2026 | Curanex Forms World Class Scientific Advisory Board | -5.0% | -0.6% |
| Feb 25, 2026 | Curanex Provides Operational Update on Key Regulatory Milestones | +4.3% | +0.8% |
| Oct 22, 2025 | Curanex Pharmaceuticals Inc. Engages Strategic Investor Relations to Enhance Investor Communications and Engagement | +14.4% | -0.5% |
Keep researching CURX
- What is Form 8-K?The SEC "current report" a public company files to disclose material events, generally within four business days of the event.
- Form 8-K explainedWhat a Form 8-K is, when it is due, and what each key item number means, from 1.01 material agreements and 2.02 earnings to 4.02 restatements and 5.02 executive changes.
- CURX financial statementsRevenue, profit, cash flow and balance sheet from Curanex Pharmaceuticals Inc's SEC filings.
Quantisnow market dataNASDAQ
CURX
Curanex Pharmaceuticals Inc
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2025
Get push alerts for CURX
Full CURX profile on Quantisnow Follow CURX and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time